NCT05832320View on ClinicalTrials.gov

Optimum Induction Therapy of Low-risk APL

NARecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Acute Promyelocytic LeukemiaInduction TherapyOral
Interventions
DRUG

Etoposide

Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given oral etoposide (50mg qd to 50mg tid). Cumulative dosage of etoposide during induction ≤1500mg.

DRUG

Daunorubicin

Introduction: RIF: 60mg/kg qd, ATRA: 25mg/m2 qd, till CR. When WBC\>4.0×109/L, patients will be given daunorubicin (20 to 40mg per dose).

Trial Locations (1)

100044

RECRUITING

Peking University Institute of Hematology, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER